The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: Impact on cancer‐specific and all‐cause mortality
Open accessAbstract
BACKGROUND: The authors evaluated sarcopenia as a predictor of cancer‐specific survival (CSS) and overall survival (OS) among patients with urothelial cancer of the bladder undergoing radical cystectomy (RC). METHODS: The lumbar skeletal muscle index (SMI) of 205 patients treated with RC for urothelial cancer between 2000 and 2007 was measured. Sarcopenia was classified according to international consensus definitions (SMI of < 55 cm 2/m 2 for men and < 39 cm 2/m 2 for women). The CSS and OS were estimated using the Kaplan‐Meier method and compared with the log‐rank test. Variables associated with CSS and all‐cause mortality were summarized with hazard ratios (HRs). RESULTS: Of 205 patients, 141 (68.8%) were sarcopenic. Patients with sarcopenia were older, but were otherwise similar to patients without sarcopenia with respect to sex, Charlson comorbidity index, American Society of Anesthesiologists score, Eastern Cooperative Oncology Group performance status, receipt of neoadjuvant chemotherapy, TNM stage of disease, and tumor grade (P > .05 for all). The median follow‐up was 6.7 years, during which time 135 patients died, including 91 who died of bladder cancer. Sarcopenic patients had significantly worse 5‐year CSS (49% vs 72%; P = .003) and OS (39% vs 70%; P = .003) compared with patients without sarcopenia. Moreover, sarcopenia was found to be independently associated with both increased CSS (HR, 2.14; P = .007) and all‐cause mortality (HR, 1.93; P = .004) on multivariable analysis. CONCLUSIONS: The presence of sarcopenia was found to significantly increase a patient's risk of CSS and all‐cause mortality after undergoing RC for bladder cancer. Cancer 2014;120:2910–2918. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539 · cited 1×
“of lymph nodes dissected (IQR) 10 (4-24) 12 (5-18) 11 (5-20) .”
Mitsiopoulos, N., Baumgartner, R. N., Heymsfield, S. B., Lyons, W., Gallagher, D., & Ross, R. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.1.115 · Cited by 1,522
Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer
Tan, B. H. L., Birdsell, L. A., Martin, L., Baracos, V. E., & Fearon, K. C. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1525 · Cited by 653
Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma
Peng, P., Hyder, O., Firoozmand, A., Kneuertz, P., Schulick, R. D., Huang, D., Makary, M., Hirose, K., Edil, B., Choti, M. A., et al. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1923-5 · Cited by 546
Reisinger, K. W., van Vugt, J. L. A., Tegels, J. J. W., Snijders, C., Hulsewé, K. W. E., Hoofwijk, A. G. M., Stoot, J. H., Von Meyenfeldt, M. F., Beets, G. L., Derikx, J. P. M., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000628 · Cited by 507
Harimoto, N., Shirabe, K., Yamashita, Y.-I., Ikegami, T., Yoshizumi, T., Soejima, Y., Ikeda, T., Maehara, Y., Nishie, A., & Yamanaka, T. (2013) · British Journal of Surgery · doi:10.1002/bjs.9258 · Cited by 504
Body composition and outcome in patients undergoing resection of colorectal liver metastases19
van Vledder, M. G., Levolger, S., Ayez, N., Verhoef, C., Tran, T. C. K., & IJzermans, J. N. M. (2012) · British Journal of Surgery · doi:10.1002/bjs.7823 · Cited by 462
Revenig, L. M., Canter, D. J., Taylor, M. D., Tai, C., Sweeney, J. F., Sarmiento, J. M., Kooby, D. A., Maithel, S. K., Master, V. A., & Ogan, K. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.06.012 · Cited by 305
Mir, O., Coriat, R., Blanchet, B., Durand, J.-P., Boudou-Rouquette, P., Michels, J., Ropert, S., Vidal, M., Pol, S., Chaussade, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037563 · Cited by 304
Frailty and sarcopenia: definitions and outcome parameters
Cooper, C., Dere, W., Evans, W., Kanis, J. A., Rizzoli, R., Sayer, A. A., Sieber, C. C., Kaufman, J.-M., Abellan van Kan, G., Boonen, S., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1913-1 · Cited by 299
Report of a WHO Expert Committee
(1986) · Journal of Environmental Conservation Engineering · doi:10.5956/jriet.15.734 · Cited by 289
Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma
Sabel, M. S., Lee, J., Cai, S., Englesbe, M. J., Holcombe, S., & Wang, S. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1976-9 · Cited by 266
Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy
Shariat, S. F., Karakiewicz, P. I., Palapattu, G. S., Amiel, G. E., Lotan, Y., Rogers, C. G., Vazina, A., Bastian, P. J., Gupta, A., Sagalowsky, A. I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0372 · Cited by 263
Nutrition and Sarcopenia: A Review of the Evidence and Implications for Preventive Strategies
Robinson, S., Cooper, C., & Aihie Sayer, A. (2012) · Journal of Aging Research · doi:10.1155/2012/510801 · Cited by 256
Exercise as a remedy for sarcopenia
Landi, F., Marzetti, E., Martone, A. M., Bernabei, R., & Onder, G. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000018 · Cited by 255
Waters, D. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6920 · Cited by 220
Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses
Baracos, V. E., & Kazemi‐Bajestani, S. M. R. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.016 · Cited by 174
Orr, R., & Fiatarone Singh, M. (2004) · Drugs · doi:10.2165/00003495-200464070-00004 · Cited by 167
Fabbro, E. D., Parsons, H. A., Warneke, C. L., Pulivarthi, K., Litton, J. K., Dev, R., Palla, S. L., Brewster, A. M., & Bruera, E. D. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0169 · Cited by 163
Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer
Antoun, S., Borget, I., & Lanoy, É. (2013) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000011 · Cited by 154
Morgan, T. M., Tang, D. H., Stratton, K. L., Barocas, D. A., Anderson, C. B., Gregg, J. R., Chang, S. S., Cookson, M. S., Herrell, S. D., Smith, J. A. J., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.034 · Cited by 152
Boorjian, S. A., Kim, S. P., Tollefson, M. K., Carrasco, A., Cheville, J. C., Thompson, R. H., Thapa, P. B., & Frank, I. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.01.010 · Cited by 128
Self-citationMorgan, T. M., Keegan, K. A., Barocas, D. A., Ruhotina, N., Phillips, S. E., Chang, S. S., Penson, D. F., Clark, P. E., Smith, J. A. J., & Cookson, M. S. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.04.089 · Cited by 120
Demark‐Wahnefried, W., Kenyon, A. J., Eberle, P., Skye, A., & Kraus, W. E. (2002) · PubMed · Cited by 74
Wan, F., Zhu, Y., Gu, C., Yao, X., Shen, Y., Dai, B., Zhang, S., Zhang, H., Cheng, J., & Ye, D. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-14 · Cited by 53
Evolution of the human life cycle
Bogin, B., & Smith, B. H. (1996) · American Journal of Human Biology · doi:10.1002/(sici)1520-6300(1996)8:6
Cited by
Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review
Shachar, S. S., Williams, G. R., Muss, H. B., & Nishijima, T. F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.030 · Cited by 1,099
Ryan, A. M., Power, D. G., Daly, L., Cushen, S. J., Ní Bhuachalla, Ē., & Prado, C. M. (2016) · Proceedings of the Nutrition Society · doi:10.1017/s002966511500419x · Cited by 542
Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span
Robbins, P. D., Jurk, D., Khosla, S., Kirkland, J. L., LeBrasseur, N. K., Miller, J. D., Passos, J. F., Pignolo, R. J., Tchkonia, T., & Niedernhofer, L. J. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-050120-105018 · Cited by 360
“Older persons with low muscle mass experience higher rates of surgical complications and infections (48), delayed recovery (49), chemotherapy toxicity (50), and disease-specific and all-cause mortality (51).”
BackgroundComputed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes
Kazemi-Bajestani, S. M. R., Mazurak, V. C., & Baracos, V. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.09.001 · Cited by 313
Tan, B. H. L., Brammer, K., Randhawa, N., Welch, N. T., Parsons, S. L., James, E. J., & Catton, J. A. (2015) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.11.040 · Cited by 277
Metadata
- Authors
- Psutka, S. P., Carrasco, A., Schmit, G. D., Moynagh, M. R., Boorjian, S. A., Frank, I., Stewart, S. B., Thapa, P., Tarrell, R. F., Cheville, J. C., & Tollefson, M. K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-05-19
- Volume
- 120
- Issue
- 18
- Pages
- 2910-2918
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1526907219
- Cited by
- 298
- References
- 30
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.